You searched for Type 1 diabetes

News and Trends 30 May 2023

Researchers identify gene expression signature to predict progression of type 1 diabetes

Researchers from Turku Bioscience Centre and InFLAMES Flagship at the University of Turku in Finland, have identified a gene expression signature that can predict the progression of type 1 diabetes.The study, led by Laura Elo and Riitta Lahesmaa, aimed to identify transcriptional changes associated with disease progression in patients with recent-onset type 1 diabetes. The […]

May 30, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

Psoriasis drug may help treat type 1 diabetes

A large clinical study is now beginning on an approved drug for treating psoriasis. The drug will be tested on patients who were recently diagnosed with type 1 diabetes. The theory is that the drug could preserve the patient’s remaining insulin production. Many hospitals in Sweden are participating in the project, which is funded by […]

January 27, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Promising drug candidate discovered for prevention of type 1 diabetes

According to a new study in Finland, type 1 diabetes could be prevented by inhibiting a gene associated with the onset of the disease. A drug based on the same mechanism has already been approved for the treatment of another autoimmune disease, psoriasis, in the U.S., which may boost the development of drug therapies for […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Adocia takes steps with implants for treatment of type 1 diabetes

French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant by achieving glycemic control without insulin injections in immunocompetent diabetic rats during a 132-day study. AdoShell Islets is an immuno-protective synthetic biomaterial containing islets of Langerhans. After implantation in diabetic animals, the islets encapsulated in AdoShell secrete insulin in […]

September 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

COUR NanoParticle technology halts Type 1 diabetes progression

COUR Pharmaceuticals has published details of a study with the Miller Lab at Northwestern University, looking at type 1 diabetes. COUR develops novel immune-modifying nanoparticles (COUR NanoParticles or CNPs) designed to reprogram the immune system in treating autoimmune disorders. The data demonstrated durable tolerance using its novel platform technology in the non-obese diabetic (NOD) model […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 6 Jun 2022

Type 1 diabetes in the crosshairs with Imagine Pharma discovery

U.S. biotech company Imagine Pharma is showcasing its discovery of Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) at the American Transplant Congress in Boston. The company said its industry breakthrough is a critical component for the potential treatment of T1D through autologous cell transplantation. T1D AIPCs are novel cell populations generated and propagated […]

June 6, 2022 - 2 minutesmins - By Jim Cornall

In Depth 3 Mar 2020

How Immunotherapy Could Stop and Prevent Type 1 Diabetes

People with type 1 diabetes need lifelong treatments of daily insulin injections to manage their condition that still leave them at risk of long-term complications. Immunotherapy could one day become an insulin-free alternative to stop, prevent, and potentially cure this chronic disease. Type 1 diabetes is an autoimmune disease where the insulin-producing beta cells in […]

March 3, 2020 - 8 minutesmins - By Clara Rodríguez Fernández

diabeloop artificial pancreas type 1 diabetes

News and Trends 2 Dec 2019

€31M Series B Funds Rollout of Artificial Pancreas in Type 1 Diabetes

The French biotech Diabeloop has raised €31M to launch an artificial pancreas device designed to automatically control the blood glucose levels of type 1 diabetes patients. According to Diabeloop, this is the biggest Series B round raised by a European company developing therapies that use artificial intelligence. The round was led by the French family […]

December 2, 2019 - 3 minutesmins - By Jonathan Smith

imcyse type 1 diabetes insulin immunotherapy

News and Trends 28 Aug 2019

Type 1 Diabetes Immunotherapy Shows Promise in Phase I

An immunotherapy designed by the Belgian biotech Imcyse to prevent type 1 diabetes has shown signs of clinical benefits and no major safety issues in a phase I trial. The phase I trial recruited 41 patients newly diagnosed with type 1 diabetes. Imcyse injected the patients with different doses of its treatment and monitored the […]

August 28, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 18 Jun 2019

Belgian Biotech’s €35M Series B to Fund Potential Type 1 Diabetes Cure

The Belgian company Imcyse has raised €35M in a Series B round to develop a potential cure for chronic autoimmune conditions including type 1 diabetes and multiple sclerosis. Imcyse will use the money to fund phase II trials of a peptide-based treatment for type 1 diabetes. The funds will also help the company to launch […]

June 18, 2019 - 2 minutesmins - By Jonathan Smith

artificial pancreas blood sugar type 1 diabetes

News and Trends 3 Oct 2018

Algorithm Proves Better Than Humans at Controlling Blood Sugar in Type 1 Diabetes

A clinical trial has shown that letting an algorithm decide the amount of insulin a person with type 1 diabetes needs can help keep blood sugar levels under control. The algorithm, being developed at the University of Cambridge, is able to predict how much insulin is needed at each point in time based on the […]

October 3, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Cheese Producing Bacteria Could Help Treat Type 1 Diabetes

News and Trends 3 Apr 2018

Cheese-Producing Bacteria Could Help Reverse Type 1 Diabetes

ActoBio Therapeutics has received permission from the FDA to start a clinical trial for a type 1 diabetes treatment that uses a bacterial strain also used in cheese production. After being cleared by the FDA, ActoBio, based in Belgium, plans to begin a PhaseIb/IIa study for its drug, AG019, to treat early-onset type 1 diabetes. What makes […]

April 3, 2018 - 2 minutesmins - By Editorial Team

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us